ALS is not an incurable disease.
It is an underfunded one.
The ALS Therapy Development Institute (ALS TDI) is proud to announce our Official Charity Partnership with the 2019 TCS New York City Marathon. Team ALS TDI features runners from all over the globe with one universal mission, finding a cure for ALS. On Sunday, November 3rd, our runners will complete the 26.2 mile run around all five boroughs of NYC to raise awareness for ALS TDI. Your donations fuel our continuous efforts to advance promising drugs and help put a stop to this terrible disease. Please join in our fight to #EndALS.
ALS TDI and its scientists actively discover and develop treatments for ALS. It is the world’s first and largest nonprofit biotech focused 100% on ALS research. Led by people with ALS and drug development experts, ALS TDI understands the urgent need to slow and stop this disease. Based in Cambridge, MA, ALS TDI has over 30 full-time, industry trained, drug discovery experts on staff. This interdisciplinary team of scientists works 24/7 in ALS TDI’s state-of-the-art laboratories and partners with pharmaceutical and biotech companies around the world.
Every 90 minutes someone is diagnosed with ALS (Amyotrophic Lateral Sclerosis), a progressive and fatal neurodegenerative disease. ALS causes muscle weakness, difficulty breathing and swallowing, and paralysis. It can affect anyone, anywhere. Most people with ALS live 2-5 years after their first symptoms. Currently, there is no effective treatment or cure. ALS TDI believes ALS is not an incurable disease; it is an underfunded one.
Learn more at www.als.net.